2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 156.215 | 130.323 | 99.911 | 71.656 | 74.213 | 79.536 | 89.854 | 92.059 | 83.436 | 84.414 |
Total Income - EUR | 159.509 | 134.289 | 100.103 | 80.237 | 74.213 | 79.536 | 89.913 | 92.072 | 83.588 | 84.414 |
Total Expenses - EUR | 152.400 | 141.636 | 108.700 | 86.279 | 70.535 | 77.222 | 84.875 | 85.595 | 85.231 | 81.798 |
Gross Profit/Loss - EUR | 7.109 | -7.347 | -8.597 | -6.042 | 3.678 | 2.315 | 5.037 | 6.477 | -1.643 | 2.617 |
Net Profit/Loss - EUR | 5.073 | -7.347 | -8.597 | -6.872 | 2.927 | 1.110 | 4.291 | 5.549 | -2.482 | 1.766 |
Employees | 4 | 4 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Adonis Pharm S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 9.334 | 8.891 | 8.378 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Assets | 56.616 | 34.425 | 33.464 | 31.704 | 31.434 | 32.560 | 40.967 | 42.573 | 36.176 | 28.810 |
Inventories | 21.200 | 8.703 | 11.155 | 7.199 | 6.792 | 9.029 | 12.605 | 14.979 | 16.740 | 14.919 |
Receivables | 28.318 | 18.676 | 15.403 | 20.377 | 21.934 | 20.795 | 25.847 | 26.964 | 18.203 | 13.356 |
Cash | 7.097 | 7.046 | 6.905 | 4.127 | 2.708 | 2.736 | 2.515 | 630 | 1.233 | 535 |
Shareholders Funds | 5.461 | -1.840 | -10.419 | -17.114 | -13.873 | -12.495 | -7.967 | -2.241 | -4.730 | -2.949 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 60.622 | 45.377 | 52.749 | 48.826 | 45.314 | 45.130 | 49.004 | 45.093 | 41.130 | 32.038 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Adonis Pharm S.r.l.